EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudie

An interpretable 1⁸F-PSMA PET/CT–MRI model for optimizing prostate biopsy decisions

Shuaitao Xiong, Jiangyu Ma, Han Li, Hui Zhu, Jingxin Yang, Zhengtong Lv, Huimin Hou, Xin Ding, Jia Chen, Yi Liu, Wenrui Xu, Chunmei Li und 6 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026-08 · 53 (10) · 5795-5810

DOI: 10.1007/s00259-026-07947-7 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 23.05.2026. Verfasst von Shuaitao Xiong und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Ger…. Hauptthemen laut MEDLINE: Edetic Acid, Magnetic Resonance Imaging, Oligopeptides, Positron Emission Tomography Computed Tomography. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, Chinese Academy of Medical Sciences Initiative for Innovative Medicine, Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Distinguishing indolent from clinically significant prostate cancer (csPCa) in biopsy-naïve men remains a diagnostic challenge, often leading to unnecessary biopsies. This study aimed to develop and externally validate an interpretable multimodal model integrating 18F-PSMA PET/CT, mpMRI, and clinical variables to predict csPCa and optimize biopsy decision-making. METHODS: This multicenter retrospective study analyzed 302 biopsy-naïve patients derived from a prospective multicenter cohort. Radiomic features were extracted from 18F-PSMA PET and mpMRI. A dual-level region-of-interest (ROI) strategy was used to capture lesion and whole-gland features. To prevent overfitting, the optimal radiomics signature was derived from the intersection of four machine learning (ML) selection algorithms, while clinical features were selected via logistic regression. Eight ML models were trained and tested with ten-fold cross-validation. A Fusion model, combining radiomics and clinical variables, was evaluated against clinical and single-modality models using AUC, decision curve analysis (DCA), and clinical impact curves (CIC). Additionally, SHapley Additive exPlanations (SHAP) values elucidated feature contributions. RESULTS: The Fusion model demonstrated robust diagnostic efficacy, achieving AUCs of 0.92 in both the internal (95% CI: 0.85-0.97) and external (95% CI: 0.83-0.99) validation cohorts. In the PI-RADS 3 subgroup, the model outperformed standard clinical assessments, yielding an excellent AUC of 0.97 (sensitivity 95.0%, specificity 86.5%). Clinically, risk stratification utilizing the Fusion model could avoid 82.9%, 75.0%, and 72.2% of unnecessary biopsies across the three cohorts, while maintaining low missed-diagnosis rates of 4.0%, 9.5%, and 6.1%, respectively. Furthermore, SHAP analysis identified PET-derived intensity and textural features as the dominant predictors, underscoring the indispensable added value of 18F-PSMA PET. CONCLUSION: This interpretable Fusion model integrating 18F-PSMA PET/CT and mpMRI demonstrated superior diagnostic performance for csPCa compared to standard clinical assessment. This approach shows potential as an effective non-invasive triage tool to support biopsy decision-making, with the potential to reduce unnecessary biopsies while maintaining oncological safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Edetic AcidMagnetic Resonance ImagingOligopeptidesPositron Emission Tomography Computed TomographyProstateProstatic NeoplasmsRadiomicsAgedHumansMaleMiddle AgedBiopsyRetrospective StudiesGlutaratesPhosphinic Acids

Stichwörter der Autor:innen

Biopsy-naïvePSMA PET/CTProstate cancerRadiomicsRisk stratification

Substanzen

(18)F-PSMA-11Edetic AcidOligopeptidesGlutaratesPhosphinic Acids

Autor:innen und Institutionen

  • Department of Urology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Me…
  • Fifth School of Clinical Medicine, Peking University, Beijing, China.
  • Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Targeted Radiopharmaceutical Development and Translational nuclear m…
  • Department of Nuclear Medicine, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Acad…
  • Department of Urology, Peking University First Hospital, Beijing, China.
  • Department of Radiology, Beijing Hospital, National Center of Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of…

ORCID-Profile: Ming Liu

Förderung

  • National High Level Hospital Clinical Research Funding
  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine
  • Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences

Zitieren

APA

Xiong, S., Ma, J., Li, H., Zhu, H., Yang, J., Lv, Z., Hou, H., Ding, X., Chen, J., Liu, Y., Xu, W., Li, C., Liu, L., Zhang, W., Gong, K., Wang, M., Huo, L., & Liu, M. (2026). An interpretable 1⁸F-PSMA PET/CT–MRI model for optimizing prostate biopsy decisions. European Journal of Nuclear Medicine and Molecular Imaging, 53(10), 5795-5810. https://doi.org/10.1007/s00259-026-07947-7

Vancouver

Xiong S, Ma J, Li H, Zhu H, Yang J, Lv Z, et al. An interpretable 1⁸F-PSMA PET/CT–MRI model for optimizing prostate biopsy decisions. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(10):5795-5810. doi:10.1007/s00259-026-07947-7

BibTeX
@article{Xiong2026,
  author = {Xiong, Shuaitao and Ma, Jiangyu and Li, Han and Zhu, Hui and Yang, Jingxin and Lv, Zhengtong and Hou, Huimin and Ding, Xin and Chen, Jia and Liu, Yi and Xu, Wenrui and Li, Chunmei and Liu, Longteng and Zhang, Wei and Gong, Kan and Wang, Miao and Huo, Li and Liu, Ming},
  title = {An interpretable 1⁸F-PSMA PET/CT–MRI model for optimizing prostate biopsy decisions},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {10},
  pages = {5795--5810},
  doi = {10.1007/s00259-026-07947-7}
}
Kostenlos starten →